ArticleActa orthopaedica2026
Plasma calprotectin as infection biomarker in hip fracture patients: a prospective cohort study.
Article in Acta orthopaedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeWe aimed to compare the diagnostic performance of plasma calprotectin in detecting infections following hip fracture surgery with 3 other biomarkers: procalcitonin (PCT), C-reactive protein (CRP), and white blood cell (WBC) count.
methodsThis prospective cohort study included surgically treated hip fracture patients aged ≥ 65 years, admitted to our department from April 2023 to August 2024. Plasma calprotectin, PCT, CRP, and WBC count were measured on postoperative day 3. The outcome was any infection within 30 days (primary) and 7 days (secondary). Biomarker performance was evaluated using receiver operating characteristic analyses in a comparative framework.
results166/550 individuals were analyzed (median age 85 years, 68% women). 19% (n = 31) and 12% (n = 20) had infection within 30 and respectively 7 days. For 30-day infections, calprotectin showed highest area under the curve (AUC) of 0.66 (95% confidence interval [CI] 0.54-0.77), followed by WBC count 0.60 (CCI 0.48-0.72), CRP 0.53 (CI 0.42-0.63), and PCT 0.51 (CI 0.40-0.63). Difference in AUC was largest between calprotectin and PCT (0.14, CI 0.00-0.29), followed by CRP (0.12, CI -0.01 to 0.26), while similar to WBC count (0.06, CI -0.05 to 0.16). For 7-day infections, AUCs were as following: calprotectin 0.70 (CI 0.58-0.82), WBC count 0.69 (CI 0.56-0.81), CRP 0.56 (CI 0.42-0.69), and PCT 0.48 (CI 0.33-0.63). Difference in AUC was largest between calprotectin and PCT (0.22, CI 0.05-0.39), followed by CRP (0.15, CI -0.02 to 0.31), while WBC count was similar (0.01, CI -0.09 to 0.12).
conclusionCalprotectin demonstrated a trend towards superior discriminatory ability for infections compared with PCT and CRP, particularly for infections within 7 days. Calprotectin provided moderate diagnostic accuracy, likewise WBC count.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.